Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.

Alnylam said that the patent application, No. 20100324120, is entitled “Lipid Formulation.” Alnylam said that it covers a variety of second-generation lipid nanoparticles including the so-called MC3 lipids used in the company's transthyretin-mediated amyloidosis drug ALN-TTR02 and its hypercholesterolemia treatment ALN-PCS.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.